

Jessica K Altman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8132372/publications.pdf>

Version: 2024-02-01

82
papers

5,641
citations

172457

29
h-index

79698

73
g-index

83
all docs

83
docs citations

83
times ranked

6468
citing authors

#	ARTICLE	IF	CITATIONS
1	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.	1.4	1,173
2	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , 2018, 378, 2386-2398.	27.0	1,092
3	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1&2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	10.7	402
4	Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. <i>Blood</i> , 2011, 118, 1248-1254.	1.4	341
5	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. <i>Blood</i> , 2019, 133, 676-687.	1.4	262
6	How I treat acute promyelocytic leukemia. <i>Blood</i> , 2009, 114, 5126-5135.	1.4	228
7	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 889-903.	10.7	205
8	International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1919-1926.	1.6	166
9	American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. <i>Blood Advances</i> , 2020, 4, 3528-3549.	5.2	113
10	A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. <i>Blood Advances</i> , 2018, 2, 825-831.	5.2	107
11	Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. <i>Leukemia Research</i> , 2013, 37, 1004-1009.	0.8	98
12	Autophagy Is a Survival Mechanism of Acute Myelogenous Leukemia Precursors during Dual mTORC2/mTORC1 Targeting. <i>Clinical Cancer Research</i> , 2014, 20, 2400-2409.	7.0	90
13	Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. <i>Blood</i> , 2013, 121, 3675-3681.	1.4	88
14	Targeting mTOR for the treatment of AML. New agents and new directions. <i>Oncotarget</i> , 2011, 2, 510-517.	1.8	85
15	Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 213-221.	4.1	81
16	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 4048-4059.	1.6	73
17	Central Role of ULK1 in Type I Interferon Signaling. <i>Cell Reports</i> , 2015, 11, 605-617.	6.4	66
18	Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4898-4906.	7.0	61

#	ARTICLE	IF	CITATIONS
19	NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1505-1512.	4.9	57
20	First-in Man, Phase 1 Study of CSL362 (Anti-IL3R [±] / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. Blood, 2014, 124, 120-120.	1.4	50
21	Targeting the CXCR4 Pathway; Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2014, 124, 386-386.	1.4	50
22	Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology American Society of Hematology Education Program, 2016, 2016, 10-15.	2.5	42
23	Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2018, 132, 564-564.	1.4	41
24	Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses. Journal of Biological Chemistry, 2008, 283, 1992-2001.	3.4	40
25	Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. Blood, 2016, 128, 410-414.	1.4	40
26	Negative Regulatory Effects of Mnk Kinases in the Generation of Chemotherapy-Induced Antileukemic Responses. Molecular Pharmacology, 2010, 78, 778-784.	2.3	39
27	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. British Journal of Haematology, 2015, 171, 471-477.	2.5	36
28	Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2. Journal of Biological Chemistry, 2008, 283, 12034-12042.	3.4	35
29	Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Current Opinion in Hematology, 2008, 15, 88-94.	2.5	32
30	Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Blood, 2019, 133, 1171-1185.	1.4	26
31	Contemporary Treatment of APL. Current Hematologic Malignancy Reports, 2014, 9, 193-201.	2.3	25
32	Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature. Journal of Hematology and Oncology, 2014, 7, 36.	17.0	25
33	Direct Binding of Arsenic Trioxide to AMPK and Generation of Inhibitory Effects on Acute Myeloid Leukemia Precursors. Molecular Cancer Therapeutics, 2015, 14, 202-212.	4.1	24
34	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal, 2022, 12, .	6.2	23
35	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American Journal of Hematology, 2019, 94, 111-117.	4.1	21
36	Gilteritinib clinical activity in relapsed/refractory FLT3-mutated acute myeloid leukemia previously treated with FLT3 inhibitors. American Journal of Hematology, 2022, 97, 322-328.	4.1	21

#	ARTICLE	IF	CITATIONS
37	Critical Roles for Rictor/Sin1 Complexes in Interferon-dependent Gene Transcription and Generation of Antiproliferative Responses. <i>Journal of Biological Chemistry</i> , 2014, 289, 6581-6591.	3.4	19
38	Optimal treatment strategies for high-risk acute promyelocytic leukemia. <i>Current Opinion in Hematology</i> , 2016, 23, 127-136.	2.5	19
39	How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 411-420.	3.8	16
40	Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e157-e162.	0.4	15
41	Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. <i>International Journal of Hematology</i> , 2017, 105, 44-51.	1.6	15
42	Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. <i>Cancer Biology and Therapy</i> , 2014, 15, 473-478.	3.4	14
43	Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 372-372.	1.4	13
44	Regulatory effects of SKAR in interferon $\hat{\pm}$ signaling and its role in the generation of type I IFN responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11377-11382.	7.1	11
45	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. <i>Blood</i> , 2014, 124, 950-950.	1.4	11
46	Unique morphologic and genetic characteristics of acute myeloid leukemia with chromothripsis: a clinicopathologic study from a single institution. <i>Human Pathology</i> , 2020, 98, 22-31.	2.0	10
47	Evorpaccept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02). <i>Blood</i> , 2021, 138, 2601-2601.	1.4	10
48	A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 770-773.	3.5	10
49	Germline <i>SH2B3</i> pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>American Journal of Hematology</i> , 2019, 94, E231-E234.	4.1	9
50	Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. <i>Echocardiography</i> , 2019, 36, 2033-2040.	0.9	9
51	Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome. <i>Leukemia</i> , 2021, 35, 2097-2101.	7.2	9
52	Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass. <i>Diagnostic Pathology</i> , 2019, 14, 26.	2.0	7
53	Inhibitory effects of Tomivosertib in acute myeloid leukemia. <i>Oncotarget</i> , 2021, 12, 955-966.	1.8	7
54	The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 797-805.	2.8	7

#	ARTICLE	IF	CITATIONS
55	Central Regulatory Role for SIN1 in Interferon \hat{I}^3 (IFN \hat{I}^3) Signaling and Generation of Biological Responses. <i>Journal of Biological Chemistry</i> , 2017, 292, 4743-4752.	3.4	6
56	An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience. <i>Human Pathology</i> , 2019, 91, 1-10.	2.0	6
57	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. <i>Blood</i> , 2017, 130, 891-891.	1.4	6
58	Comparison of myeloid neoplasms with nonclassic 3q26.2/ <i>MECOM</i> versus classic inv(3)(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of <i>MECOM</i> activation. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 71-80.	2.8	6
59	Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. <i>British Journal of Haematology</i> , 2022, 197, 736-744.	2.5	6
60	A new purpose for an old drug: inhibiting autophagy with clarithromycin. <i>Leukemia and Lymphoma</i> , 2012, 53, 1255-1256.	1.3	5
61	Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 243-250.	1.6	5
62	A Population-Based Study In Acute Promyelocytic Leukemia (APL) Suggests a Higher Early Death Rate and Lower Overall Survival Than Commonly Reported In Clinical Trials: Data From the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer Registry In the United States Between 1992-2007. <i>Blood</i> , 2010, 116, 872-872.	1.4	5
63	NME1 and NME2 as markers for myeloid leukemias. <i>Leukemia and Lymphoma</i> , 2012, 53, 1441-1442.	1.3	4
64	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	4.1	4
65	Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations. <i>Blood</i> , 2018, 132, 1458-1458.	1.4	4
66	Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia. <i>Blood</i> , 2014, 124, 24-24.	1.4	4
67	A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents. <i>Blood</i> , 2010, 116, 1857-1857.	1.4	3
68	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMG632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4440-4440.	1.4	2
69	Prospects for mTOR targeting in adult T cell leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 525-526.	1.3	1
70	Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0249087.	2.5	1
71	Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses. <i>Blood</i> , 2014, 124, 3751-3751.	1.4	1
72	Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. <i>Blood</i> , 2020, 136, 5-7.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience. <i>Blood</i> , 2020, 136, 14-16.	1.4	1
74	The molecular basis of acute myeloid leukemia. , 0, , 751-768.		0
75	SNPing away to individualize induction therapy for acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 742-743.	1.3	0
76	Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkinâ€™s Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.. <i>Blood</i> , 2005, 106, 5455-5455.	1.4	0
77	Targeting the mTOR Pathway Suppresses the Growth of Acute Myeloid Leukemia (AML) Progenitors and Enhances Arsenic Trioxide Induced Antileukemic Responses.. <i>Blood</i> , 2006, 108, 1898-1898.	1.4	0
78	Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkinâ€™s Lymphoma. <i>Blood</i> , 2011, 118, 4499-4499.	1.4	0
79	Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. <i>Blood</i> , 2012, 120, 2024-2024.	1.4	0
80	Dose-Intense Etoposide and Cyclophosphamide without Stem Cell Transplantation for the Treatment of Primary Refractory and Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 4314-4314.	1.4	0
81	Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7004-7004.	1.6	0
82	Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML. <i>Blood</i> , 2019, 134, 3413-3413.	1.4	0